Marshall Wace, LLP Tcr2 Therapeutics Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $164,383 - $322,602	-68,493 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$4.58 - $8.34 $544,745 - $991,959	-118,940 Reduced 63.46%	68,493 $320,000
Q3 2021 Nov 15, 2021	BUY	$8.44 - $18.35 $1.58 Million - $3.44 Million	187,433 New	187,433 $1.6 Million
Q2 2021 Aug 13, 2021	SELL	$16.41 - $24.71 $364,482 - $548,833	-22,211 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $34,788 - $58,157	1,707 Added 8.33%	22,211 $491,000

Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $389,576 - $669,045	20,504 New	20,504 $634,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.